▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #363 by analyst upside · 2026-08-12
INO
Inovio Pharmaceuticals, Inc.
Healthcare · Market Cap $79M · P/E 0x
ANALYST PRICE TARGET
+261.3%
implied upside to consensus target
Current Price $0.77
Consensus Target $2.77
Bull Target $4.0
Bear Target $1.8
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
0
Hold
2
Sell
0
52-Week Low $0.56
52-Week High $2.98
YTD Return -54.7%
FUNDAMENTALS
Market Cap $79M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.58
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.56
52-Week High $2.98
Current Price $0.77
Bear Target $1.8
Bull Target $4.0
● Now $0.77 ● Target $2.77
TRADING DATA
Avg Volume 2.7M
YTD Return -54.7%
Analyst Count 3
Consensus Buy
Upside to Target +261.3%
Last Updated 2026-08-12

ANALYST SUMMARY

Inovio Pharmaceuticals, Inc. (INO) is currently trading at $0.77 with a Wall Street consensus price target of $2.77, implying potential upside of 261.3% over the next 12 months. 3 analysts currently cover INO, with a consensus rating of Buy - 33% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.0, while the most cautious has a target of $1.8.

INO operates in the Healthcare sector with a market capitalisation of $79M. The stock is down 54.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.56 – $2.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SPRO +225.2%
Spero Therapeutics, Inc.
$71M · P/E 4.6x · Hold
FBIO +321.5%
Fortress Biotech, Inc.
$87M · P/E 0.8x · Buy
XTNT +321.9%
Xtant Medical Holdings, Inc.
$45M · P/E 32.0x · Strong Buy
NAGE +292.3%
Niagen Bioscience, Inc.
$244M · P/E 16.2x · Buy
CCLD +151.0%
CareCloud, Inc.
$104M · P/E 34.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for INO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Neutral → Neutral 2026-06-01 31% win rate (48 calls)
Piper Sandler reit
Overweight → Overweight 2025-11-14 14% win rate (7 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-08-14 31% win rate (48 calls)
Piper Sandler ● Initiated
Overweight 2025-07-09 14% win rate (7 calls)
RBC Capital reit
Sector Perform → Sector Perform 2025-05-14 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2025-05-14 14% win rate (7 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2025-03-19 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2025-03-19 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
13
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →